Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 93

Results For "operations"

923 News Found

Syngene Q3 revenue up 13% to Rs. 585 Cr
News | January 22, 2021

Syngene Q3 revenue up 13% to Rs. 585 Cr

EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.

Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business

Shilpa Medicare CFO resigns
People | January 20, 2021

Shilpa Medicare CFO resigns

The commercial production in the SML was started in November 1989.

Latest Stories

Thermo Fisher Scientific appoints Anoopa Menon as Director

Lilly drug cuts risk of cancer progression, extends survival in advanced breast cancer trial

EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging